Abstract

Bioactive Phytocompounds (BPCs) naturally found in plants, hold immense potential for cancer treatment. However, their limitations like poor solubility, bioavailability and stability hinder their effectiveness. This review explores how nanotechnology can overcome these limitations and empower phytochemicals in the fight against drug-resistant cancer. Despite advancements, conventional therapies (surgery, radiation, chemotherapy) often suffer from side effects and drug resistance. Understanding the complex signaling pathways involved in cancer development is crucial for designing targeted therapies. Phytochemicals offer diverse biological activities against cancer, but their inherent limitations restrict their use. They can induce apoptosis, inhibit growth, modulate inflammation, and bolster the immune response. Nanocarriers encapsulating phytochemicals enhance their solubility, stability, and bioavailability, enabling targeted delivery to cancer cells while minimizing harm to healthy tissues. Intricate nanocarriers are programmed for controlled release and specific targeting based on cancer cell markers. Although phytochemicals exhibit diverse anti-cancer activities, their limitations restrict their use. Nanotechnology offers a game-changer, enhancing solubility, and stability, and enabling targeted delivery to cancer cells, minimizing harm to healthy tissues. Exciting future advancements include intricate nanocarriers programmed for controlled release and personalized therapy tailored to individual patients. This intersection of phytochemicals, cancer research, and nanotechnology offers a beacon of hope, paving the way for personalized, safe, and effective therapies, bringing us closer to a world free from the devastating effects of drug-resistant cancer.

Keywords:Bioactive phytocompounds; Nanoformulation; Cancer; Targeted drug-delivery